SRK, as co-lead counsel, has just moved for approval of $65.87 million in settlements with all of the defendants in the long-running Provigil antitrust litigation. SRK has asked Judge Mitchell Goldberg of the U.S. District Court for the Eastern District of Pennsylvania to give preliminary approval to settlements between consumers and health plans and defendants Teva (which acquired defendants Cephalon and Barr), Mylan and Ranbaxy. These settlements, once approved, would allow class members to recover for overcharges they paid on Provigil and its generic versions from 2006 through the present. The next step is for the Court to grant preliminary approval and allow the plaintiffs to send notice to potential class members across the country. A copy of the Memorandum in support of Settlement can be found here. For more information, contact lead attorney John Macoretta at 215-496-0300 or email@example.com.